Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Profound Medical ( (TSE:PRN) ) is now available.
Profound Medical Corp. announced record preliminary unaudited revenues for the third quarter of 2025, with an anticipated revenue range of $5.2 million to $5.3 million, marking an 84% to 87% increase from the previous year. The company attributes this growth to the expansion of its TULSA-PRO installed base and increased system utilization. The gross margin is expected to rise to approximately 72%, up from 64% the previous year, reflecting improved operational efficiency. The company plans to release its full financial results on November 13, 2025, followed by a conference call to discuss the developments.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that specializes in developing and marketing customizable, incision-free therapies for the ablation of diseased tissue. The company is known for its TULSA-PRO technology, which combines real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for treating prostate diseases. Profound also markets Sonalleve, a platform for treating uterine fibroids and palliative pain from bone metastases.
Average Trading Volume: 13,995
Technical Sentiment Signal: Sell
Current Market Cap: C$238.6M
See more data about PRN stock on TipRanks’ Stock Analysis page.